Pathogenic and clinical trial of N-acetylcysteine (Fluimucil) in idiopathic pulmonary fibrosis
https://doi.org/10.18093/0869-0189-2005-0-1-34-41
Abstract
The aim of this study was to investigate free radical and lipid disorders in idiopathic pulmonary fibrosis (IPF), to assess clinical efficacy of Fluimucil and to substantiate its administration in different stages of the disease.
We observed 127 IPF patients, of them 59 were treated typically with prednisolone, colchicines, or azathioprin, 68 ones received immunosuppressors and Fluimucil. The diagnosis of IPF was verified morphologically in open lung biopsy samples. The patients’ age was 25 to 74 yrs, the mean age, 46.7 ± 9.8 yrs. A control group included 20 healthy donors, the mean age, 41.2 ± 1.2 yrs.
N-acetylcysteine (Fluimucil, Zambon group) was administered initially IV 1800 mg a day for 14 days, then orally 1 800 mg a day for a month, then 600 mg a day for 3 months. Clinical and free radical conditions were monitored before the treatment and 3, 6 and 12 months starting the therapy.
Fluimucil improved thrombocyte antioxidant activity and plasma antioxidant activity, reduced CT signs of IPF, provided a stable growth in FEV1 and FVC (by 10 % and 12 % respectively) and DLco. Fluimucil was well-tolerated, adverse effects (nausea, stomach ache) were noted in 7 patients (10.2 %). Thus, the results confirmed antioxidant efficacy of Fluimucil in IPF. The long-term administration of Fluimucil combined with the immunosuppressive drugs in IPF patients was safe and reasonable as this inhibited progression of the disease.
About the Authors
E. N. Popova
Кафедра терапии и профессиональных заболеваний, кафедра патологической физиологии ММА им. И.М.Сеченова
Russian Federation
Russian Federation
B. M. Kornev
Кафедра терапии и профессиональных заболеваний, кафедра патологической физиологии ММА им. И.М.Сеченова
Russian Federation
Russian Federation
K. U. Reznikova
Кафедра терапии и профессиональных заболеваний, кафедра патологической физиологии ММА им. И.М.Сеченова
Russian Federation
Russian Federation
O. V. Kondarova
Кафедра терапии и профессиональных заболеваний, кафедра патологической физиологии ММА им. И.М.Сеченова
Russian Federation
Russian Federation
References
1. American Thoracic Society / European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias, 2001. Am. J. Respir. Crit. Care Med. 2002; 165: 277—304.
2. Hubbard R., Johnston I., Coultas D.B., Britton J. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax 1996; 51: 711—716.
3. Коган А.X., Попова Е.Н., Болевич C. и др. Генеpация активныx фоpм киcлоpода лейкоцитами кpови и альвеоляpными макpофагами, cодеpжание пpодукта пеpекиcного окиcления липидов малонового диальдегида и антипеpекиcная защита пpи cаpкоидозе и идиопатичеcком фибpозиpующем альвеолите. Пульмонология 1996; 1: 50—57.
4. Попова Е.Н., Архипова Д.В., Коган Е.А. и др. Роль эндотелиальной дисфункции и неоангиогенеза в развитии пневмосклероза и легочной гипертензии при обычной интерстициальной пневмонии. Пульмонология 2004; 3: 16—22.
5. Чучалин А.Г., Соодаева С.К., Авдеев С.Н. Флуимуцил: механизмы действия и значение в терапии органов дыхания. М.: Zambon Group; 2004.
6. Colby T.V. Pathological approach to idiopathic interstitial pneumonias: useful points for clinicians. Breath 2004; 1 (1): 43—49.
7. Liebow A.A., Carrington C.B. The interstitial pneumonias. In: Frontiers of pulmonary radiology. 1-st ed. New York: Grune & Stratton; 1969. 102—141.
8. Lynch J.P. et al. Usual interstitial pneumonia. Semin. Respir. Crit. Care Med. 2001; 22 (4): 461—467.
9. Rosai J. Rosai and Ackerman’s surgical pathology. 9-th ed. New York; 2004; 1: 359—459.
10. Zander D.S. Idiopathic interstitial pneumonias and the concept of the trump card. Chest 2004; 125 (2): 359— 360.
11. International consensus statement prepared by an Assembly on Clinical Problems. Idiopathic pulmonary fibrosis: diagnosis and treatment. Am. J. Respir. Crit. Care Med. 2000; 161: 646—664.
12. Selman M., Lin H.M., Montano M. et al. Surfactant protein A and B genetic variants predispose to Idiopathic pulmonary fibrosis. Hum. Genet. 2003; 113: 542—550.
13. Bergeron A., Soler P., Kambouchner M. et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur. Respir. J. 2003; 22 (1): 69—76.
14. Kamp D.W. Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited. Chest 2003; 124 (4): 1187—1190.
15. Thannickal V.J., Toews G.B., White E.S. et al. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 2004; 55: 395—417.
16. Behr J. Diagnostik der idiopathischen Lungenfibrose. Pneumologie 2001; 55: 144—148.
17. Richeldi L., Davies H.R., Ferrara G., Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane library. Cochrane Rev. 2003; viss.4.
18. Behr J., Maier K., Degenkolb B. et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 1997; 156: 1897—1901.
19. Pietra G.G., Capron F., Sterwart S. Pathologic assessment of vasculopathies in pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 19 (3): 25—32.
20. Rahman I., van Schadewijk A.A., Crowther A.J. et al. 4- Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 490—495.
21. Arnon R., Raz I., Chajek-Shaul T. et al. Amiodarone pulmonary toxicity presenting as a solitary lung mass. Chest 1998; 93: 425—428.
22. Stahlmann R., Lode H. Safety overview: Toxicity, adverse effects and drug interactions. In: Andriole V.T., ed. The quinolones. San Diego: Academic Press; 1998. 403—414.
23. Ziegenhagen M.W., Muller-Quernheim J. Idiopathic pulmonary fibrosis (IPF): diagnosis, differential diagnosis and current therapeutic options. Dtsch. Med. Wschr. 2004; 129 (10): 494—498.
24. Global initiative for chronic obstructive lung disease. NHLBI / WHO workshop report. — 2004.
25. De Benedetto F., Aceto A., Formisano S. et al. Long-term treatment with N-acetylcistein (NAC) decreases hydrogen peroxide levelin exhaled air of patients ith moderate COPD. Am. J. Respir. Crit. Care Med. 2001; 163: A725.
26. Tajima S., Oshikawa K., Tominaga S., Sugiyama Y. The increase in serum-soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003; 124: 1206—1214.
27. Strieter R.M. To clot or not to clot, that is the question in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167 (12): 1589—1590.
Review
For citations:
Popova E.N., Kornev B.M., Reznikova K.U., Kondarova O.V. Pathogenic and clinical trial of N-acetylcysteine (Fluimucil) in idiopathic pulmonary fibrosis. PULMONOLOGIYA. 2005;(1):34-41. (In Russ.) https://doi.org/10.18093/0869-0189-2005-0-1-34-41
Views:
565
Email this article 